LRMR - Larimar Therapeutics, Inc.
2.1
-0.590 -28.095%
Share volume: 2,122,866
Last Updated: 05-06-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$2.69
-0.59
-0.22%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 10-30-2024 | 03-24-2025 | 04-30-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | ||||
| Operating expenses | 16.734 M | 24.599 M | 18.264 M | 31.293 M | 31.188 M | |
| Selling general and admin | 3.795 M | 4.917 M | 4.345 M | 4.555 M | 4.636 M | |
| Research and development | 12.939 M | 19.682 M | 13.919 M | 26.738 M | 26.552 M | |
| Total expenses | 16.734 M | 24.599 M | 18.264 M | 31.293 M | 31.188 M | |
| 47.00% | -25.75% | 71.34% | -0.34% | |||
| Operating income | -16.734 M | -24.599 M | -18.264 M | -31.293 M | -31.188 M | |
| Ebit | -14.654 M | -21.627 M | -15.499 M | -28.824 M | -29.281 M | |
| Pretax income | -14.654 M | -21.627 M | -15.499 M | -28.824 M | -29.281 M | |
| 47.58% | -28.33% | 85.97% | 1.59% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -14.654 M | -21.627 M | -15.499 M | -28.824 M | -29.281 M | |
| -47.58% | 28.33% | -85.97% | -1.59% |
